GI Innovation Inc
KOSDAQ:358570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GI Innovation Inc
Short-Term Investments
GI Innovation Inc
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Short-Term Investments
₩14.4B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Short-Term Investments
₩84.6B
|
CAGR 3-Years
55%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Short-Term Investments
₩126.2B
|
CAGR 3-Years
30%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Short-Term Investments
₩43.8B
|
CAGR 3-Years
795%
|
CAGR 5-Years
245%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Short-Term Investments
₩362.6B
|
CAGR 3-Years
64%
|
CAGR 5-Years
31%
|
CAGR 10-Years
34%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Short-Term Investments
₩3B
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Short-Term Investments?
Short-Term Investments
14.4B
KRW
Based on the financial report for Dec 31, 2024, GI Innovation Inc's Short-Term Investments amounts to 14.4B KRW.
What is GI Innovation Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 3Y
-52%
Over the last year, the Short-Term Investments growth was -60%. The average annual Short-Term Investments growth rates for GI Innovation Inc have been -52% over the past three years .
